LITERATURE REVIEW: POLYPHARMACOTHERAPY AND ITS NEUROLOGICAL EFFECTS IN THE ELDERLY IN POLAND AND EUROPE
Authors:
- Martyna Maria KnopekMKMartyna Maria Knopek
- Paulina PrudzicPPPaulina Prudzic
- Maciej LazarekMLMaciej Lazarek
- Kamila Prusinowska PrusinowskaKPKamila Prusinowska Prusinowska
- Aleksasndra Sipowicz-WoźniakASAleksasndra Sipowicz-Woźniak
- Aleksandra H. PiotrowskaAPAleksandra H. Piotrowska
- Zuzanna Kordyś-WyrobekZKZuzanna Kordyś-Wyrobek
- Ewelina FlegielEFEwelina Flegiel
Open Access
- 25 June 2026
- journal article
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Abstract
In recent years both in Poland and Europe there have been observed progressive demographic changes and aging of the population. Polypharmacy can be defined as the simultaneous and regular use of at least five different drugs and is particularly often used in elderly patients due to the multimorbidity. According to some sources, elderly people take between two and nine different medications daily, of which even about 60% are inappropriate. The aim of this paper is to summarize information on polypharmacy in seniors in order to plan it as best as possible and at the same time to avoid potential adverse effects, with particular emphasis on the nervous system. One of the most significant for polypharmacy is the age structure of the society. Poland is one of the European countries where the fastest growth of this ratio is observed. Huge problem seems to be the system of educating doctors, which is not adjusted to the changing demographics of the society. Furthermore, one of the factors contributing to polypharmacy is the excessive consumption of dietary supplements by Poles, especially geriatric patients - almost half of Poles consume them regularly. Polypharmacy can be defined as the simultaneous use of at least five different drugs. It is particularly often used in elderly patients due to the multimorbidity and lack of healthcare access. The advantage of polypharmacotherapy is faster achievement of target values, which may improve the patient-doctor relationship, while the disadvantage is the increased risk of side effects. Polypharmacy is a significant problem in the European elderly, to avoid its negative effects, drugs with high bioavailability, short half-lives and a broad therapeutic spectrum are the best choice.Keywords
This publication has 29 references indexed in Scilit:
- Polypharmacy in patients with epilepsy: A nationally representative cross-sectional studyEpilepsy & Behavior, 2020
- Polypharmacy in Older Adults: Practical Applications Alongside a Patient CaseThe Journal for Nurse Practitioners, 2020
- Association between anticholinergic drug burden and mortality in older people: a systematic reviewEuropean Journal of Clinical Pharmacology, 2019
- A discussion of the unresolved 2016/17 plans for regulating the Polish dietary supplements marketHealth Policy, 2019
- Microalgal food supplements from the perspective of Polish consumers: patterns of use, adverse events, and beneficial effectsJournal of Applied Phycology, 2017
- Cumulative Use of Strong Anticholinergics and Incident DementiaJAMA Internal Medicine, 2015
- Management of stress urinary incontinence2012
- Drugs with anticholinergic properties: cognitive and neuropsychiatric side-effects in elderly patientsNeurological Sciences, 2009
- Clinically relevant drug interactions with antiepileptic drugsBritish Journal of Clinical Pharmacology, 2005
- The Importance of Drug Interactions in Epilepsy TherapyEpilepsia, 2002